- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about ALPMY
Recent news which mentions ALPMY
Super Bowl Commercials 2023: The Complete List Of Super Bowl LVII Ads And The Companies Behind Them
February 13, 2023
From Benzinga
Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts
January 31, 2023
From Benzinga
From Benzinga
What Is Going on With Taysha Gene (TSHA) Stock Today?
October 25, 2022
From InvestorPlace
From Benzinga
Astellas' Menopause Drug Under FDA Review
August 18, 2022
From Benzinga
From Benzinga
7 Best Biotech Stocks to Buy in July 2022
July 08, 2022
From InvestorPlace
Sutro Biopharma Stock Surges On Cancer Treatment Pact
June 28, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Got $1,000? Here's a Dirt-Cheap Big Pharma Stock to Buy
March 15, 2022
From Motley Fool
From Benzinga
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
February 15, 2022
From Benzinga
Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November
December 04, 2021
From Motley Fool
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
December 02, 2021
From Benzinga
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
September 27, 2021
From Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
September 14, 2021
From Benzinga
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
September 14, 2021
From Benzinga
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
September 01, 2021
From Benzinga
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
September 01, 2021
From Benzinga
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
August 20, 2021
From Benzinga
Here's What Recent News From the FDA Means for AstraZeneca
August 20, 2021
From Motley Fool
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
August 20, 2021
From Benzinga
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
August 11, 2021
From Benzinga
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.